Biofrontera AG
Ansprechpartner: Investor Relations
Tel.: +49 (0) 214 87 63 20
Public disclosure of inside information according to article 17 MAR

Biofrontera AG: Cologne Higher Regional Court grants approval of capital increase

Leverkusen (pta/07.01.2021/17:45 UTC+1) Leverkusen, Germany, January 07, 2021 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the "Company"), an international biopharmaceutical company, announces that the Cologne Higher Regional Court has granted the release of the capital increase resolved by the Annual General Meeting on May 28, 2020.

On May 28, 2020, the Annual General Meeting had resolved, with the required majority, to increase the Company's share capital by issuing up to 8,969,870 new registered no-par value shares against cash contributions while granting an indirect subscription right (agenda item 6).

One shareholder had filed an action for rescission and annulment against this resolution in order to block the entry of the capital increase in the Commercial Register and thus the implementation of the capital increase. As a result, the Company filed the application for release with the Cologne Higher Regional Court, which was granted today.

With today's positive decision by the Cologne Higher Regional Court, the capital increase can now be implemented in a timely manner. This will enable the Company to move forward with its strategic research and development projects and its products' market penetration with maximum speed.

Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen
ISIN: DE0006046113
WKN: 604611
Contact: Biofrontera AG
Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290


Emitter: Biofrontera AG
Hemmelrather Weg 201
51377 Leverkusen
Contact Person: Investor Relations
Phone: +49 (0) 214 87 63 20
ISIN(s): DE0006046113 (Share)
Stock Exchange(s): Regulated Market in Dusseldorf, Frankfurt; Free Market in Berlin, Munich, Stuttgart, Tradegate
Other Stock Exchanges: Nasdaq